SCHEMBL5047079

SCHEMBL5047079

CC1(C)CCC(C)(C)c2c(SCc3ccc(F)cc3)cc(C(=O)/C=C/c3ccc(C(=O)O)c(O)c3)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 4/20 0.38
RARB P10826 4/20 0.38
RARG P13631 3/20 0.38
CTSL P07711 1/20 0.37
CXCL12 P48061 1/20 0.37
RXRA P19793 2/20 0.36
CYP26A1 O43174 1/20 0.35
MAOB P27338 3/20 0.35
MAOA P21397 1/20 0.35
PTPN1 P18031 1/20 0.34
DHODH Q02127 1/20 0.34
TNFRSF1A P19438 1/20 0.34
MAPT P10636 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047081 1.00 RARA (0.38) RARARARBRARGCTSLCXCL12
SCHEMBL5049636 0.92 RARA (0.38) RARARARBRARGCXCL12RXRA
SCHEMBL5049635 0.92 RARA (0.38) RARARARBRARGCXCL12RXRA
SCHEMBL5048453 0.90 MAOB (0.42) RARARARBRARGMAOBMAOA
SCHEMBL5048451 0.90 MAOB (0.42) RARARARBRARGMAOBMAOA
SCHEMBL5047126 0.90 RARB (0.48) RARARARBRARGRXRACYP26A1
SCHEMBL5047125 0.90 RARB (0.48) RARARARBRARGRXRACYP26A1
SCHEMBL5050811 0.84 RARA (0.43) RARARARBRARGRXRAPTPN1
SCHEMBL5050810 0.84 RARA (0.43) RARARARBRARGRXRAPTPN1
SCHEMBL5050808 0.84 RARA (0.43) RARARARBRARGRXRAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed
EP-1513803-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS Galderma Research & Development, S.N.C. (FR) 2005-03-16 EP disclosed
WO-2003101945-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARA 1/4885RARB 2/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.